Type 2 Diabetes-Related Variants Influence the Risk of Developing Prostate Cancer: A Population-Based Case-Control Study and Meta-Analysis
Metadata
Show full item recordAuthor
Sánchez Maldonado, José Manuel; Cabrera Serrano, Antonio José; Robles Fernández, Inmaculada; Arenas Rodríguez, Verónica; Cano Gutiérrez, Blanca; López Nevot, Miguel Ángel; Fernández Puerta, Laura; Cózar Olmo, José Manuel; Jurado Chacón, Manuel; Lorente Acosta, José Antonio; Álvarez Cubero, María Jesús; Sáinz Pérez, JuanEditorial
MDPI
Materia
Prostate cancer Genetic susceptibility Type 2 diabetes-related variants
Date
2022-05-12Referencia bibliográfica
Sánchez-Maldonado, J.M... [et al.]. Type 2 Diabetes-Related Variants Influence the Risk of Developing Prostate Cancer: A Population-Based Case-Control Study and Meta-Analysis. Cancers 2022, 14, 2376. [https://doi.org/10.3390/cancers14102376]
Sponsorship
FIBAO foundation (Granada, Spain); Instituto de Salud Carlos III PI12/02688 PI17/02256 PI20/01845Abstract
In this study, we have evaluated whether 57 genome-wide association studies (GWAS)-identified common variants for type 2 diabetes (T2D) influence the risk of developing prostate cancer (PCa) in a population of 304 Caucasian PCa patients and 686 controls. The association of selected single nucleotide polymorphisms (SNPs) with the risk of PCa was validated through meta-analysis of our data with those from the UKBiobank and FinnGen cohorts, but also previously published genetic studies. We also evaluated whether T2D SNPs associated with PCa risk could influence host immune responses by analysing their correlation with absolute numbers of 91 blood-derived cell populations and circulating levels of 103 immunological proteins and 7 steroid hormones. We also investigated the correlation of the most interesting SNPs with cytokine levels after in vitro stimulation of whole blood, peripheral mononuclear cells (PBMCs), and monocyte-derived macrophages with LPS, PHA, Pam3Cys, and Staphylococcus Aureus. The meta-analysis of our data with those from six large cohorts confirmed that each copy of the FTOrs9939609A, HNF1B(rs7501939T), HNF1B(rs75721T), HNF1B(rs4430796G), and JAZF1(rs10486567A) alleles significantly decreased risk of developing PCa (p = 3.70 x 10(-5), p = 9.39 x 10(-54), p = 5.04 x 10(-54), p = 1.19 x 10(-71), and p = 1.66 x 10(-18), respectively). Although it was not statistically significant after correction for multiple testing, we also found that the NOTCH2(rs10923931T) and RBMS1(rs7593730) SNPs associated with the risk of developing PCa (p = 8.49 x 10(-4) and 0.004). Interestingly, we found that the protective effect attributed to the HFN1B locus could be mediated by the SULT1A1 protein (p = 0.00030), an arylsulfotransferase that catalyzes the sulfate conjugation of many hormones, neurotransmitters, drugs, and xenobiotic compounds. In addition to these results, eQTL analysis revealed that the HNF1B(rs7501939), HNF1B(rs757210), HNF1B(rs4430796), NOTCH2(rs10923931), and RBMS1(rs7593730) SNPs influence the risk of PCa through the modulation of mRNA levels of their respective genes in whole blood and/or liver. These results confirm that functional TD2-related variants influence the risk of developing PCa, but also highlight the need of additional experiments to validate our functional results in a tumoral tissue context.